[1]
Sani, G.; Perugi, G.; Tondo, L. Treatment of bipolar disorder in a lifetime perspective: Is lithium still the best choice? Clin. Drug Investig., 2017, 37(8), 713-727.
[http://dx.doi.org/10.1007/s40261-017-0531-2] [PMID: 28477315]
[http://dx.doi.org/10.1007/s40261-017-0531-2] [PMID: 28477315]
[2]
Malhi, G.S.; Outhred, T. Therapeutic mechanisms of lithium in bipolar disorder: Recent advances and current understanding. CNS Drugs, 2016, 30(10), 931-949.
[http://dx.doi.org/10.1007/s40263-016-0380-1] [PMID: 27638546]
[http://dx.doi.org/10.1007/s40263-016-0380-1] [PMID: 27638546]
[3]
Geddes, J.R.; Goodwin, G.M.; Rendell, J.; Azorin, J-M.; Cipriani, A.; Ostacher, M.J.; Morriss, R.; Alder, N.; Juszczak, E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (balance): A randomised open-label trial. Lancet, 2010, 375(9712), 385-395.
[http://dx.doi.org/10.1016/S0140-6736(09)61828-6] [PMID: 20092882]
[http://dx.doi.org/10.1016/S0140-6736(09)61828-6] [PMID: 20092882]
[4]
Salloum, I.M.; Cornelius, J.R.; Daley, D.C.; Kirisci, L.; Himmelhoch, J.M.; Thase, M.E. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Arch. Gen. Psychiatry, 2005, 62(1), 37-45.
[http://dx.doi.org/10.1001/archpsyc.62.1.37] [PMID: 15630071]
[http://dx.doi.org/10.1001/archpsyc.62.1.37] [PMID: 15630071]
[5]
Vieta, E.; Berk, M.; Schulze, T.G.; Carvalho, A.F.; Suppes, T.; Calabrese, J.R. Bipolar disorders; Nat Rev Dis Prim, 2018, p. 4.
[6]
Maletic, V.; Raison, C. Integrated neurobiology of bipolar disorder. Front. Psychiatry, 2014, 5, 98.
[http://dx.doi.org/10.3389/fpsyt.2014.00098] [PMID: 25202283]
[http://dx.doi.org/10.3389/fpsyt.2014.00098] [PMID: 25202283]
[7]
Gignac, A.; McGirr, A.; Lam, R.W.; Yatham, L.N. Recovery and recurrence following a first episode of mania: A systematic review and meta-analysis of prospectively characterized cohorts. J. Clin. Psychiatry, 2015, 76(9), 1241-1248.
[http://dx.doi.org/10.4088/JCP.14r09245] [PMID: 25845021]
[http://dx.doi.org/10.4088/JCP.14r09245] [PMID: 25845021]
[8]
Aringhieri, S.; Carli, M.; Kolachalam, S.; Verdesca, V.; Cini, E.; Rossi, M.; McCormick, P.J.; Corsini, G.U.; Maggio, R.; Scarselli, M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol. Ther., 2018, 192, 20-41.
[http://dx.doi.org/10.1016/j.pharmthera.2018.06.012] [PMID: 29953902]
[http://dx.doi.org/10.1016/j.pharmthera.2018.06.012] [PMID: 29953902]
[9]
Carlson, G.A.; Kotov, R.; Chang, S.W.; Ruggero, C.; Bromet, E.J. Early determinants of four-year clinical outcomes in bipolar disorder with psychosis. Bipolar Disord., 2012, 14(1), 19-30.
[http://dx.doi.org/10.1111/j.1399-5618.2012.00982.x] [PMID: 22329469]
[http://dx.doi.org/10.1111/j.1399-5618.2012.00982.x] [PMID: 22329469]
[10]
Pisano, S.; Pozzi, M.; Catone, G.; Scrinzi, G.; Clementi, E.; Coppola, G.; Milone, A.; Bravaccio, C.; Santosh, P.; Masi, G. Putative mechanisms of action and clinical use of lithium in children and adolescents: A critical review. Curr. Neuropharmacol., 2019, 17(4), 318-341.
[http://dx.doi.org/10.2174/1570159X16666171219142120] [PMID: 29256353]
[http://dx.doi.org/10.2174/1570159X16666171219142120] [PMID: 29256353]
[11]
Lipska, K.; Gumieniczek, A.; Filip, A.A. Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges. Acta Pharm., 2020, 70(3), 291-301.
[http://dx.doi.org/10.2478/acph-2020-0021] [PMID: 32074065]
[http://dx.doi.org/10.2478/acph-2020-0021] [PMID: 32074065]